Clinical decisions
Apixaban dosing: start with the indication
Apixaban does not have one dose for every indication. Adult nonvalvular atrial fibrillation, acute DVT or PE, and recurrence prevention use different labeled regimens. Age and renal information matter, but first identify which rule belongs to the indication.
Sources checked October 5, 2026. Independent educational content, not NABP exam questions or individual treatment advice.
Count the exact NVAF criteria
The FDA label lists age at least 80 years, body weight at most 60 kg and serum creatinine at least 1.5 mg/dL. At least two are required for the 2.5 mg twice-daily NVAF regimen. Being elderly alone does not satisfy this rule.
Notice cutoff direction and units. The creatinine criterion is a serum concentration, not an eGFR. Other renal circumstances, contraindications and interactions still need review beyond this counting exercise.
Separate the adult VTE phases
Adult DVT/PE treatment is 10 mg twice daily for the first seven days, followed by 5 mg twice daily. Reduction of recurrent DVT/PE risk uses 2.5 mg twice daily after at least six months of treatment. Those phases are not interchangeable.
A 2.5 mg tablet can be appropriate for one indication but inadequate for another. Establish whether the patient is starting acute treatment, continuing treatment or entering recurrence prevention. Do not replace the VTE regimen with the NVAF age-weight-creatinine count.
Review the factors outside the count
The label has additional instructions for combined strong P-glycoprotein/CYP 3 A 4 inhibitors and recommends avoiding combined strong inducers. Check the actual medicine and current label rather than assuming every CYP 3 A 4 drug has the same effect.
Boxed warnings address premature discontinuation and spinal/epidural hematoma. This dose-selection lesson is not permission to stop anticoagulation before a procedure. Periprocedural planning and bleeding are separate clinical decisions.
Test the rule with a near-boundary case
A weight of exactly60 kg meets the NVAF weight criterion; a weight of61 kg does not. An age of80 meets the age criterion. Read the comparison symbols rather than rounding a patient into eligibility. A single criterion does not become two because renal function is described vaguely as impaired.
For practice, create a three-column checklist for age, weight and serum creatinine, then count. After that, reread the indication and medication list. This order catches both arithmetic-style cutoff errors and the larger clinical error of using the correct rule for the wrong indication.
A worked case
Compare NVAF patients: age 82, weight 58 kg, creatinine 1.2 mg/dL; and age 82, weight 74 kg, creatinine 1.2 mg/dL. Assume no other adjustment or contraindication.
- The first meets age and weight criteria: two of three.
- The second meets only age.
- Under these NVAF assumptions, the first meets the 2.5 mg twice-daily rule; the second remains at the usual 5 mg twice-daily labeled regimen.
Answer: Confirm the indication, then count criteria.
Try it before reading the answer
Write the key fact, decision and safety check first. These are original practice exercises, not recalled exam items.
1. Does age 81 alone satisfy the NVAF reduction rule?
No. At least two of the three specified criteria are needed.
2. What is the initial labeled adult acute DVT/PE regimen?
10 mg twice daily for seven days, then 5 mg twice daily, subject to full label and patient review.
3. When does the adult 2.5 mg recurrence-prevention regimen apply?
After at least six months of DVT/PE treatment, not as the default acute starting dose.
Continue learning
Put the topic into a study planSources and scope
Source dates and limits matter. Follow the current official source for clinical or regulatory decisions. Examples are simplified teaching cases, not prescribing, diagnostic or compounding instructions. Check the full current guidance and individual clinical context.